Tms (4891) · RiskRestated
Competition and clinical trial delays in the acute ischemic stroke field
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Intensifying Competition and Clinical Trial Delay Risk in the Acute Ischemic Stroke Market for TMS-007A theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Tissue plasminogen activator (t-PA) is the only product approved by the FDA for acute ischemic stroke treatment, while multiple drug candidates, including Tenecteplase, Sovateltide (PMZ-1620) and LT3001, are in clinical development.」
The Company continues to disclose potential competition from Tenecteplase, Sovateltide, LT3001 and biosimilars, as well as risks of delays or discontinuation caused by slow patient enrollment or partner decisions. - FY2023First statedAnnual report
「The biotechnology and pharmaceutical industries include potential competitors, such as large pharmaceutical companies, with substantial financial and technical resources for developing and selling prescription drugs. If competitors advance their R&D in the stroke field, TMS-007’s competitive position could decline.」
The Company highlights the possibility that competing candidates, biosimilars and difficulties enrolling patients could reduce TMS-007’s competitive position or delay or terminate its trial.